CRPC: SBRT shows benefit in oligoprogressive disease

  • Triggiani L & al.
  • World J Urol
  • 11 Mar 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Stereotactic body radiation therapy (SBRT) may be an effective treatment approach in patients with oligoprogressive castration-resistant prostate cancer (CRPC).
  • No serious adverse events were reported with SBRT.

Why this matters

  • SBRT has shown benefit in oligometastatic castration-sensitive prostate cancer, but its role in CRPC is not known.
  • Prospective evaluation of study findings is warranted.

Study design

  • Multicenter study of 86 patients (117 lesions) with oligoprogressive CRPC who received SBRT.
  • Funding: None.

Key results

  • Median follow-up was 30.7 months.
  • Median new metastasis-free survival was 12.3 (95% CI, 5.5-19.1) months.
  • 1- and 2-year distant PFS was 52.3% and 33.7%, respectively.
  • 26 patients underwent a second course of SBRT.
  • Median systemic treatment-free survival was 21.8 (95% CI, 17.8-25.8) months.
  • 1-year systemic treatment-free survival was 72.1%.
  • Total radiation dose showed significant association with systemic treatment-free survival (biologically effective dose >100 vs ≤100 Gy; P=.004).
  • 3 patients experienced grade 1/2 acute intestinal or genitourinary toxicities.
  • 2 patients experienced grade 1/2 late intestinal or genitourinary toxicities.

Limitations

  • Retrospective design; lack of comparator group.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit